Trend of Seroincidence of Hepatitis B Virus Infection  in Eastern Libya: A 10-Years Study from Tobruk  Medical Center

Osamah Miftah

doi:10.64516/vsxc6f72

Authors

Osamah Miftah Department of Medical Laboratory, Faculty of Medical Technology, University of Tobruk, Libya Author

DOI:

https://doi.org/10.64516/vsxc6f72

Keywords:

Hepatitis B Virus, Seroincidence, Tobruk Medical Center, Retrospective Study

Abstract

Hepatitis B virus (HBV) is a significant blood transmitted viral infection. It causes a serious liver infection and can be transmitted to the uninfected individuals via contact with the body fluids of infected individuals. HBV infection remains a main health concern for both health workers and patients in health care settings worldwide. The aim of this study is to estimate the seroincidence of HBV in individuals who attended Tobruk Medical Center for different medical or surgical conditions from January 2010 to April 2020. Also, to estimate its distribution based on age and sex, geographical distribution and nationalities of the cases during the study period; in addition to increase awareness about the spread and the way of control of this viral infection in the community. A retrospective study of 10 years at Tobruk Medical Centre, eastern Libya. Medical records department of the hospital follow the guidelines of international classification of diseases-10 for coding the diseases. The research estimates the frequency and distribution of HBV infection based on age, sex, geographical distribution and nationalities during the study period from January 2010 to April 2020. 113 cases (mean age 40.12 ± 15.7) were found positive for HBV infection over the study period. 41.6 % of the cases were males and 58.4 % were females. The HBV infection was most prevalent in the older age groups of 20->50 years. The frequency of the disease according to the nationality was: Libyan (89.4%), Egyptian (4.4%), Sudanese (1.8%) and small other percentages from other nationalities. The frequency of the disease according to the region was: Tobruk (86.5%), Derna (7.1 %) and small other percentages from other regions. This study reported a significant decline in the incidence of HBV infection in the last five years and this decline may be because of the weakening of health screening services. The best way to control or eradicate HBV infection in the community is by vaccination of all newborn and high-risk groups, and following stricter standard precautions in health-care-providing centres, in addition to surveillance of occupationally acquired HBV infections.

References

1. Sinn DH, Kim SE. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat. 2019;26:1465–72.

2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.

3. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis and therapy. Clin Microbiol Rev. 2020;33:e00046–19.

4. World Health Organization (WHO). Hepatitis B virus Fact sheet. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b [Accessed Jul 2021].

5. Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31:249–55.

6. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410.

7. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351–66.

8. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.

9. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.

10. Daw MA, El-Bouzedi A. Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population-based survey. BMC Infect Dis. 2014;14:17.

11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

12. Elzouki AN. Hepatitis B infection in Libya: the magnitude of the problem. Libyan J Infect Dis. 2008;2:20–5.

13. Ismail F, Shambesh M, Aboutwerat A, Elbackush M. Serological and molecular characterization of total hepatitis B core antibodies in blood donors in Tripoli, Libya. Libyan J Infect Dis. 2010;4.

14. Ismail F, Shambesh M, Aboutwerat A, Elnifro E. Serological and molecular characterization of total hepatitis B core antibodies in blood donors in Tripoli, Libya. Second Infectious and Endemic Diseases Scientific Conference; 2009 May 15–18; Tripoli, Libya.

15. Shambesh MK, Franka E, Ismail F, Gebril N, Azabi K. Significance of screening anti-HBc among Libyan blood donors: a preliminary study. 32nd BBTS Annual Conference; Harrogate, UK. Transfus Med. p.64–5.

16. Shambesh MK, Franka EA, Ismail FF, Gebril NM, Azabi KA, Amar F. Anti-HBc and HBV-DNA among blood donors in North Africa; Western Libya. Int Blood Res Rev. 2015;3:152–9.

17. Shambesh MKA, Franka EA, Ismail FF, Elosta MA. Occult hepatitis B virus infection among blood donors; North Middle Libya. Int Blood Res Rev. 2016;6(2):1–7.

18. El-Nabi SH, El-Garawani I, Ismail F, Abdelsameea E. Anti-HBc and hepatitis B virus DNA among HBsAg-negative blood donors from the main central blood bank units in Eastern Libya. Transfus Med. 2020;30(5):401–5.

19. Ismail F, Farag A, Ilah MA. Occurrence of hepatitis B, hepatitis C and HIV infections among individuals undergoing preemployment and premarital medical examination in Mediterranean Port City Tobruk, Libya. Int Blood Res Rev. 2016;6(4):1–6.

20. Alsharif F, Ismail F, Ilah A. Incidence of HBV infections detected during pre-employment checkup in Tripoli, Libya. Second Medical Research Conference; 2017 Jan 30; Tripoli University.

21. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000;13:385–407.

22. Daw MA, Siala IM, Warfalli MM, Muftah MI. Seroepidemiology of hepatitis B virus markers among hospital health care workers. Saudi Med J. 2000;21:1157–60.

23. Elzouki AN, Elgamay SM, Zorgani A, Elahmer O. Hepatitis B and C status among health care workers in the five main hospitals in eastern Libya. J Infect Public Health. 2014;7:534–41.

24. Centers for Disease Control and Prevention (CDC). Prevention of Hepatitis in Healthcare Settings. 2011. Available from: https://www.cdc.gov/hai/organisms/hepatitis.html [Accessed Jul 2021].

25. Bell DM, Shapiro CN, Ciesielski CA, Chamberland ME. Preventing bloodborne pathogen transmission from health-care workers to patients: the CDC perspective. Surg Clin North Am. 1995;75:1189–203.

26. Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR Suppl. 1989;38:1.

27. Denes AE, Smith JL, Maynard JE, Doto IL, Berquist KR, Finkel AJ. Hepatitis B infection in physicians: results of a nationwide seroepidemiologic survey. JAMA. 1978;239:210–2.